



Resolution n° 12-2017-e

No cost extension of the Project “Market entry of an improved solid protease inhibitor-based first line antiretroviral combination therapy for infants and young children with HIV/AIDS” by DNDi

Recalling Unitaid Board Resolution UNITAID/EB17/2012/R07 of December 2012 in which the Board approved the commitment of up to US\$ 17,336,000 for the project entitled “Market entry of an improved solid protease inhibitor-based first line antiretroviral combination therapy for infants and young children with HIV/AIDS” (the “Project”) implemented by Drugs for Neglected Diseases *initiative* (DNDi);

Having taken note of the Secretariat’s update to the Board with regard to this Project, the Board authorizes a no cost extension of the Project for up to an additional nineteen months, subject to the signature of the legal agreement between DNDi and Unitaid.

Lead Organisation: Drugs for Neglected Diseases initiative (DNDi)

Project Duration: 1 June 2017 – 31 December 2018 (19 months)

Celso Amorim
Chair of the Unitaid Executive Board

Date: AUGUST, 25, 2017.